Results of a prospective, randomized double-blind study comparing standard vs low-dose OKT3 induction therapy.
Alloway
R
R
University of Tennessee, Memphis 38163.
Kotb
M
M
Hathaway
D K
DK
Gaber
L W
LW
Vera
S R
SR
Gaber
A O
AO
D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006084:Graft Rejection; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D014184:Transplantation, Homologous
D016853:Muromonab-CD3